We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LGND icon
276
CALL
Ligand Pharmaceuticals
LGND
$5.8B
– –
-673
Closed -$2.83M
LLY icon
277
CALL
Eli Lilly
LLY
$1.09T
– –
-1,719
Closed -$10.1M
MRK icon
278
CALL
Merck
MRK
$324B
– –
-2,113
Closed -$11.4M
NKTR icon
279
PUT
Nektar Therapeutics
NKTR
$2.31B
– –
-97
Closed -$1.77M
OMER icon
280
Omeros
OMER
$839M
– –
-20,000
Closed -$241K
PFE icon
281
CALL
Pfizer
PFE
$144B
– –
-4,533
Closed -$13.8M
PFE icon
282
PUT
Pfizer
PFE
$144B
– –
-685
Closed -$2.09M
PRTA icon
283
CALL
Prothena Corp
PRTA
$441M
– –
-225
Closed -$862K
SPY icon
284
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$779B
– –
-1,338
Closed -$25M
TCRT icon
285
Alaunos Therapeutics
TCRT
$4.71M
– –
-737
Closed -$410K
TCRT icon
286
PUT
Alaunos Therapeutics
TCRT
$4.71M
– –
-10
Closed -$667K
TLPH icon
287
CALL
Talphera
TLPH
$66.4M
– –
-23
Closed -$563K
TMO icon
288
CALL
Thermo Fisher Scientific
TMO
$213B
– –
-1,100
Closed -$13.2M
TMO icon
289
Thermo Fisher Scientific
TMO
$213B
– –
-38,630
Closed -$4.64M
XBI icon
290
State Street SPDR S&P Biotech ETF
XBI
$10B
– –
-131,235
Closed -$6.23M
BPTH
291
DELISTED
Bio-Path Holdings Inc
BPTH
– –
-828
Closed -$8.78M
DMK
292
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
– –
-868
Closed -$386K
ISEE
293
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-15,944
Closed -$570K
ISEE
294
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-400
Closed -$1.43M
MNTA
295
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-1,729
Closed -$2.01M
MNTA
296
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-18,274
Closed -$213K
MNTA
297
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-382
Closed -$445K
AVEO
298
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-57,342
Closed -$857K
SGYP
299
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
– –
-377,908
Closed -$718K
TSRO
300
DELISTED
TESARO, Inc.
TSRO
– –
-98,500
Closed -$2.63M
9 10 11
12
13

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.